2Firsts Talks with Nancy Loucas, Asia-Pacific THR Leader: Giving a Voice to the Overlooked Consumer

Jun.18.2025
Ahead of the upcoming Global Forum on Nicotine (GFN), 2Firsts interviews Nancy Loucas, Executive Coordinator of CAPHRA, on why consumers must have a voice in tobacco harm reduction policymaking—and how she’s helping them speak up.

[By Taco Tuinstra | 2Firsts] Nancy Loucas: Helping Consumers Find Their Voice

 

As part of its media partnership with the Global Forum on Nicotine (GFN), scheduled for June 19-21 in Warsaw, 2Firsts reached out to several scheduled speakers, and asked them about their respective fields of expertise.

 

Nancy Loucas has been fighting for vapers’ rights to be able to access the tools they need to become smokefree and remain smoke free since 2015, when she co-founded the Aotearoa Vapers Community Advocacy in New Zealand.

 

She is also the executive director of the Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA), which supports consumer tobacco harm reduction (THR) advocacy organizations and activities throughout the Asia Pacific region and beyond.

 

Under Loucas’ leadership, CAPHRA established numerous initiatives to give a voice to the consumer, who she says is often overlooked in the debates. Such programs include the “Right2Vape” testimonial database (set up in collaboration with the Consumer Advocates for Smoke-free Alternatives Association in the United States) and the “Right2Switch” petition, which urges the World Health Organization to regulate based on science and include consumers into its decision-making process.

 

At the GNF, Loucas will be hosting a workshop to help consumers effectively communicate their message, which fits well with the overall conference theme of “Challenging Perceptions – Effective Communication for Tobacco Harm Reduction.” 2Firsts asked Loucas about her aspirations and the challenges facing consumers.

 

2Firsts Talks with Nancy Loucas, Asia-Pacific THR Leader: Giving a Voice to the Overlooked Consumer

Nancy Loucas | Image: AVCA

 

2Firsts: What inspired you to become a consumer advocate in the THR field?

 

Loucas: Watching relatives become ill and eventually die from smoking-related diseases. Watching relatives not receive appropriate medical care for nonsmoking-related illnesses, because of their smoking status. Not wanting my children to lose their mother, as I lost mine from smoking, at an early age. Wanting others to have the same opportunity I had to move off the deadly stuff.

 

2Firsts: How do you define THR, and why is the consumer perspective essential in this space?

 

Loucas: Short answer: My definition of THR is saving lives with innovation. Long answer: It is the prevention of smoking related death and disease through the use of innovative nicotine products that help people to move away from smoking and unsafe oral tobacco use.

 

2Firsts: What challenges do consumers face in communicating their positions?

 

Loucas: The main challenge is being listened to. The Machine, as I like to call tobacco control, likes to denigrate and dehumanize consumers and their lived experiences by labeling them as “anecdotes,” as opposed to scientists, experts or researchers. They do this by calling us names, accusing us of nefarious activities to the benefit of tobacco companies, and [by] excluding us from a seat at the table.

 

Another challenge arises from external NGO's [nongovernmental organizations] coming into countries without actually caring about that country, its culture or its problems, but only wanting to control the narrative with their views, their solutions, their policies. In Asia Pacific, a western mindset doesn't translate well at all.

 

2Firsts:What strategies have you found effective in elevating consumer perspectives in regulatory or scientific arenas?

 

Loucas:The one really good thing about the wider THR community is that the consumers, scientists and some regulatory people do communicate with respect and consideration. At conferences, everyone engages; the pro-THR scientists treat the consumers as equals.

 

In Asia Pacific—with the exception of Australia and India—there's less of a barrier between advocates on the one hand and public health and/or government on the other. That could be due to a number of factors, but I think it's mainly about networking in collective societies. Asia Pacific folks aren't very individualistic and going on about “my rights as an individual.” There are consumers who are on government committees about regulation; there are consumers who regularly engage with regulatory folks on a personal level.

 

The elevation of the consumer perspective is not so much the issue as is the backlash and misinformation from externally funded tobacco control-NGOs pushing a scripted narrative.

 

2Firsts:In your view, how can consumers be meaningfully involved in policy development on nicotine and tobacco products?

 

Loucas:Consumers can be—and should be—meaningfully involved in policy development as the decisions made directly impact them. The best way to do that is to engage. Some consumers are afraid they do not have the skills or the “right” to speak to policy/public health/government people, but with some support, some training and focus, they are the kingmakers really. My main comment to consumers who are reticent to engage is this "elected officials work for you, not the other way around.”

 

2Firsts:What are the primary benefits you hope participants will gain from your GFN workshop?

 

Loucas:The GFN is about learning, community and support. The workshop is about helping people succeed in their advocacy and feel supported and confident in their mission.

 

2Firsts has been a media partner of the Global Forum on Nicotine (GFN) for three consecutive years.


2Firsts welcomes article submissions, interview opportunities, or commentary. Please contact us at info@2firsts.com or connect with 2Firsts CEO Alan Zhao on LinkedIn here.

 

China Discloses First Criminal Case Over Counterfeit Vapes Disguised as “Medical Nebulizers” and “Zero-Nicotine” Products
China Discloses First Criminal Case Over Counterfeit Vapes Disguised as “Medical Nebulizers” and “Zero-Nicotine” Products
Chinese authorities have disclosed the country’s first reported criminal case involving counterfeit vapes marketed as “medical nebulizers” and “zero-nicotine” products. Authorities determined that the products involved were counterfeit vapes and pursued criminal charges for producing and selling counterfeit goods. According to the report, the case resulted in the seizure of 347,000 counterfeit vape pods and 53,700 vape devices, with physical goods valued at 22.13 million yuan.
Aug.04
Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
U.S. President Donald Trump has chosen White House health policy aide Heidi Overton to lead the Food and Drug Administration, Bloomberg reported, citing a person familiar with the matter. Overton currently works on health policy at the White House and previously held a senior role at the America First Policy Institute. If confirmed by the Senate, she would take over an FDA that has experienced months of senior-level turnover. The agency regulates products representing roughly one-fifth of U.S. consumer spending, including e-cigarettes, drugs, vaccines and much of the food supply.
News
Aug.19
Australia’s One Nation Proposes 75% Tobacco Tax Cut, Says Lower Prices Could Hit Illicit Market
Australia’s One Nation Proposes 75% Tobacco Tax Cut, Says Lower Prices Could Hit Illicit Market
Australia’s One Nation party has proposed cutting tobacco excise by 75%, arguing that lower legal cigarette prices could narrow the gap with illicit tobacco and reduce demand for black-market products. The proposal comes as Australia continues expanding enforcement against illicit tobacco supply chains through border controls, retail inspections and organised-crime investigations. Supporters argue high taxes have contributed to illicit-market growth, while opponents warn that lower tobacco prices could undermine public-health goals. The proposal is a party policy position and has not been adopted by the Australian government.
Aug.18
UK Sets Oct. 29 Start for New Vape Retail Rules Covering Age Checks, Giveaways and Discounts
UK Sets Oct. 29 Start for New Vape Retail Rules Covering Age Checks, Giveaways and Discounts
The UK Department of Health and Social Care published new guidance on Aug. 11 outlining the next phase of retail rules under the Tobacco and Vapes Act 2026, which will take effect on Oct. 29, 2026. The measures extend the minimum age of sale of 18 to all vaping and consumer nicotine products and restrict proxy purchasing, promotional giveaways and substantial discounts. Relevant offences in England, Wales and Scotland may carry a £200 fixed penalty notice, while persistent offenders can face temporary sales bans.
Aug.12
Product | Summo 150K Introduces Refillable Design With Up to 150,000 Puffs, Exploring a New High-Capacity Vape Format
Product | Summo 150K Introduces Refillable Design With Up to 150,000 Puffs, Exploring a New High-Capacity Vape Format
Summo has introduced the Summo 150K Refillable Disposable Vape, entering the ultra-high-puff vape segment with a claimed capacity of up to 150,000 puffs. The device combines a 40ml dual e-liquid system, transparent tank design, dual mesh coils and a 900mAh rechargeable battery, using a refillable structure to differentiate itself from conventional disposable vapes. The product appeared on overseas online retail channels including Vapesourcing and VapeBarTime between late June and early July 2026.
Jul.22
Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List
Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List
Charlie’s Holdings said the U.S. Food and Drug Administration notified the company on June 23, 2026, that 30 PACHA vape SKUs with submitted PMTAs had been tentatively identified for inclusion on a planned public-facing FDA webpage. Under enforcement guidance issued by FDA in May, the webpage is intended to identify certain unauthorized products for which the agency generally does not intend to prioritize enforcement of premarket authorization requirements. Charlie’s disclosed the development alongside second-quarter revenue of $3.8 million, up 116% year over year.
Aug.25